FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL

Season 10 Episode 9  ·  Jan 25, 2024, 07:55 PM

Headliner
Share
Subscribe

Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated CLL/SLL; key efficacy and safety data from the BRUIN trial; and guidelines for pirtobrutinib use in clinical practice in the CLL/SLL patient population.

Share
Subscribe
Next
Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air